Citigroup
ACRV icon

Citigroup’s Acrivon Therapeutics ACRV Stock Holding History

Citigroup’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11 Buy
+6
New +$10 ﹤0.01% 5593
2026
Q1 		– Sell
-14,592
Closed -$35.2K – 5897
2025
Q4 		$35.2K Sell
14,592
-1,713
-11% -$3.72K ﹤0.01% 4691
2025
Q3 		$29.5K Sell
16,305
-16,077
-50% -$22.6K ﹤0.01% 4668
2025
Q2 		$38.5K Buy
32,382
+21,223
+190% +$29.1K ﹤0.01% 4891
2025
Q1 		$22.7K Sell
11,159
-1,173
-10% -$6.32K ﹤0.01% 5061
2024
Q4 		$74.2K Buy
12,332
+1,116
+10% +$8.11K ﹤0.01% 4959
2024
Q3 		$78.5K Buy
11,216
+6,134
+121% +$48.3K ﹤0.01% 4873
2024
Q2 		$29.5K Buy
5,082
+546
+12% +$4.4K ﹤0.01% 4873
2024
Q1 		$32.4K Buy
4,536
+2,489
+122% +$11.6K ﹤0.01% 4861
2023
Q4 		$10.1K Buy
2,047
+1,817
+790% +$9.6K ﹤0.01% 5194
2023
Q3 		$2.2K Sell
230
-2,560
-92% -$29.6K ﹤0.01% 4938
2023
Q2 		$36.2K Buy
2,790
+2,588
+1,281% +$31.3K ﹤0.01% 4793
2023
Q1 		$2.56K Buy
+202
New +$3.39K ﹤0.01% 5061

Other funds holding ACRV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AWM
AAF Wealth Management Westborough, Massachusetts $271M AUM 24.26% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Citigroup's ACRV Position: Q2 2026 in Review

Citigroup opened a new position in Acrivon Therapeutics (ACRV) in Q2 2026: 6 shares worth $11. The stake represents ﹤0.01% of the portfolio and ranks #5593 among its holdings. This is a return to the name: Citigroup previously reported a position in ACRV as recently as Q4 2025.

Citigroup first reported a position in ACRV in Q1 2023 and has held it in 13 quarters since. The position peaked at $78.5K in Q3 2024. 9 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • Citigroup held 6 shares of Acrivon Therapeutics worth $11 as of Q2 2026.
  • Acrivon Therapeutics was a new Citigroup position in Q2 2026.
  • Acrivon Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5593 holding.
  • Citigroup first reported a position in Acrivon Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Citigroup's Acrivon Therapeutics position peaked at $78.5K in Q3 2024.
  • 9 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.